Immunotherapy

Proton Pump Inhibitor and Antibiotic Use May Reduce the Benefit of Immunotherapy in NSCLC

Baseline use of proton pump inhibitors (PPIs) and, to a lesser extent, antibiotics was associated with poorer outcomes in patients…

1 week ago

Early Time-of-Day Immunotherapy Shows Survival Benefit in Lung Cancer Trial

In a Chinese phase 3 trial (LungTIME-C01) involving 210 patients with advanced non-small cell lung cancer, administering anti-PD-1 immunotherapy before…

5 months ago

This website uses cookies.